目的 研究多西他賽聯(lián)合順鉑和替吉奧膠囊治療宮頸癌的臨床療效和安全性。方法 將2011年1月-2013年12月就診于重慶市大足區(qū)人民醫(yī)院的宮頸癌患者120例隨機分為聯(lián)合治療、多西他賽、替吉奧膠囊組，每組40例，3組患者均在1個療程的前3天每天靜脈滴注注射用順鉑30 mg/m²，聯(lián)合治療組在此基礎(chǔ)上在第1天靜脈滴注多西他賽注射液，60 mg/m²，同時口服替吉奧膠囊60 mg/m²，2次/d，連服2周。多西他賽組靜脈滴注多西他賽注射液，用法用量同聯(lián)合治療組。替吉奧膠囊組口服替吉奧膠囊，用法用量同治療組。21 d為一個療程，3組患者共治療2個療程。比較3組患者治療后的臨床療效、腫瘤直徑和不良反應發(fā)生情況。結(jié)果 治療后3組患者的腫瘤直徑均顯著減小，同組治療前后差異有統(tǒng)計學意義（P<0.05、0.01）；治療后，多西他賽組和替吉奧膠囊組患者腫瘤直徑較聯(lián)合治療組大，差異有統(tǒng)計學意義（P<0.05）。聯(lián)合治療組、多西他賽組和替吉奧膠囊組的總有效率分別為95.0%、77.5%、80.0%，后兩組的總有效率均顯著低于聯(lián)合治療組，差異有統(tǒng)計學意義（P<0.05）。3組患者均發(fā)生化療的毒副反應，發(fā)生率為100%，其中主要包括惡心、嘔吐、腹瀉、脫發(fā)、腎功能損傷、骨髓抑制。3組患者不良反應發(fā)生率差異無統(tǒng)計學意義。結(jié)論 多西他賽聯(lián)合順鉑和替吉奧膠囊治療宮頸癌具有良好的臨床療效，可顯著減小腫瘤直徑，且不良反應可控。

Objective To investigate the efficacy and safety of docetaxel combined with cisplatin and Gimeracil Capsule in the treatment of cervical cancer. Methods Cervical cancer patients (120 cases) who came to the People's Hospital of Dazu Country from January 2011 to December 2013 were randomly divided into combined treatment, docetaxel, and Gimeracil Capsule groups (n=40). The patients in three groups were given cisplatin for iv injection (30 mg/m²) on the first three days of one course. The patients in the combined treatment group were iv administered with Docetaxel Injection (60 mg/m²), and at the same time, they were po administered with Gimeracil Capsule (60 mg/m²), twice daily for two weeks. The patients in the docetaxel group were iv administered with Docetaxel Injection, and the usage and dosage were the same as those in the combined treatment group. The patients in the Gimeracil Capsule group were po administered with Gimeracil Capsules, and the usage and dosage were the same as those in the combined treatment group. One course was 21 d in three groups and all the patients accepted the treatment for two courses. The clinical efficacy, tumor diameter, and adverse reaction of chemotherapy in three groups were compared. Results After treatment, tumor diameter in three groups were significantly decreased, and the difference was statically significant in the same group before and after treatment (P < 0.05, 0.01). After treatment, tumor diameters in docetaxel and Gimeracil Capsule groups were larger than that in the combined treatment group, with significant difference (P < 0.05). The total effective rates of combined treatment, docetaxel, and Gimeracil Capsule groups were 95.0%, 77.5%, and 80.0%, respectively, and the total effective rate of the last two groups were significantly lower than that in the combined treatment group, with significant difference (P < 0.05). There were side reactions of chemotherapy in three groups, and the incidence was 100%, which mainly included nausea, vomiting, diarrhea, hair loss, kidney damage, and bone marrow suppression. There was no statistically significant difference in the incidence of adverse reactions in three groups. Comclusion Docetaxel combined with cisplatin and Gimeracil Capsule has a good clinical efficacy in the treatment of cervical cancer, which can significantly reduce the tumor diameter and the adverse reactions are under control.

國家自然科學基金資助項目（30901596）